
Opinion|Videos|September 18, 2024
Evaluating Imaging Agents in Oligometastatic Prostate Cancer: A Comparative Analysis of Gallium-Based and Non-Gallium-Based Options
Author(s)Jaideep S. Sohi, MD, Jeremie Calais, MD
Medical experts conduct a comparative assessment of gallium-based and non-gallium-based imaging agents to determine their efficacy in detecting and characterizing oligometastatic prostate cancer.
Advertisement
Video content above is prompted by the following:
- Can you discuss the advantages and limitations of different imaging agents commonly used in identifying oligometastatic disease in prostate cancer, such as gallium-based agents versus non-gallium-based agents?
- Are you aware of any differences in lesion detection rates or staging accuracy between gallium vs non- gallium-based PET imaging agents?
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Advertisement
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears Radiotherapy System with 20-Fold Increase in PET Imaging Sensitivity for Tumor Detection
2
FDA Clears 1.5T MRI Platform with Helium-Free Technology
3
Study: MRI May Help Predict Outcomes in Treatment for Triple-Negative Breast Cancer
4
Top Five Radiology Podcasts in 2025
5



























